OncoMatch/Clinical Trials/Triple-Negative Breast Cancer (TNBC)
Triple-Negative Breast Cancer (TNBC) Clinical Trials
OncoMatch filters Triple-Negative Breast Cancer (TNBC) trials by the molecular markers that determine eligibility — BRCA1, BRCA2, CD274, PIK3CA, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Triple-Negative Breast Cancer (TNBC) trials
These are the molecular markers most commonly required or evaluated in Triple-Negative Breast Cancer (TNBC) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Triple-Negative Breast Cancer (TNBC) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Merck Sharp & Dohme LLC
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Merck Sharp & Dohme LLC
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Jina Pharmaceuticals Inc.
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Fudan University
How OncoMatch finds Triple-Negative Breast Cancer (TNBC) trials for you
AI reads the protocol
Every Triple-Negative Breast Cancer (TNBC) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Triple-Negative Breast Cancer (TNBC) and mark your biomarker results — BRCA1, BRCA2, CD274 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.